Abstract: A cellulose based anti-viral/anti-microbial coating.

Abstract: Entity resolution techniques for matching entity records from different data sources are provided. In one technique, an entity record from a source database is identified along with multiple data items included therein. Each data item corresponds to an attribute of multiple source attributes. For one of the data items that corresponds to a first source attribute, multiple target attributes are identified. A first query is generated that includes the data items and associates the data item with each of the multiple target attributes. A second query that is different than the first query is also generated. Two searches are performed of a target database: one based on the first query and the other based on the second query. A scoring model generates multiple scores, one for each search result. It is determined whether the entity record matches an entity record in the target database based on the set of scores.

Abstract: Entity resolution techniques for matching entity records from different data sources are provided. In one technique, an entity record from a source database is identified along with multiple data items included therein. Each data item corresponds to an attribute of multiple source attributes. For one of the data items that corresponds to a first source attribute, multiple target attributes are identified. A first query is generated that includes the data items and associates the data item with each of the multiple target attributes. A second query that is different than the first query is also generated. Two searches are performed of a target database: one based on the first query and the other based on the second query. A scoring model generates multiple scores, one for each search result. It is determined whether the entity record matches an entity record in the target database based on the set of scores.

Abstract: Techniques for managing multiple computing systems are provided. A system comprises a content delivery system (CDS) and an entity identification system (EIS). The CDS causes a content item that is associated with a content delivery campaign to be delivered over a computer network to a computing device of a user. The CDS detects that the user performed an action relative to the content item and, in response, creates an action record that indicates a particular entity associated with the user and that indicates an account that is associated with the content item and causes the action record to be made available to the EIS. The EIS, based on the account indicated in the action record, identifies a particular account from among multiple accounts indicated in an account database and searches the particular account for an entity (if any) that matches the particular entity.

Abstract: In one aspect, TEMPO-cellulose structures and method of making the same are described herein. Briefly, a method of synthesizing TEMPO-cellulose comprises disposing cellulose in an aqueous medium, disposing first and second oxidizing agents in the aqueous medium and oxidizing hydroxyl groups of the cellulose via the first and second oxidizing agents in the presence of a 2,2,6,6-tetramethylpiperidine 1-oxyl radical (TEMPO) catalyst.

Abstract: Techniques for managing multiple computing systems are provided. A system comprises a content delivery system (CDS) and an entity identification system (EIS). The CDS causes a content item that is associated with a content delivery campaign to be delivered over a computer network to a computing device of a user. The CDS detects that the user performed an action relative to the content item and, in response, creates an action record that indicates a particular entity associated with the user and that indicates an account that is associated with the content item and causes the action record to be made available to the EIS. The EIS, based on the account indicated in the action record, identifies a particular account from among multiple accounts indicated in an account database and searches the particular account for an entity (if any) that matches the particular entity.

Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.

Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.

Abstract: This invention provides a protein comprising (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp120 envelope polypeptide portion of a gp140 envelope of (i) an HIV-I KNH1144 isolate, or a quasi-species thereof, or (ii) an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gp140 envelope of (i) the HIV-I KNH1144 isolate or such quasi-species thereof, or (ii) the HIV-I 5768.4 isolate or such quasi-species thereof. This invention also provides nucleic acids encoding such proteins, vectors, host cells and compositions thereof. Also provided are trimeric complexes (‘trimers’) of these proteins and methods of using such trimers to combat HIV-I infection.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

Abstract: This invention provides a DNA which upon transcription produces an RNA encoding a modified HIV-1 gp140 polypeptide, which polypeptide upon cleavage produces a modified gp120 and a modified ectodomain of gp41 which together form a complex exhibiting enhanced binding to HIV-1 neutralizing antibodies and reduced binding to HIV-1 non-neutralizing antibodies, wherein the modifications comprise an A492C mutation in gp120 and a T596C mutation in gp41, said mutations being numbered by reference to the HIV-1 isolate JR-FL, and resulting in a disulfide bond between gp120 and ectodomain gp41 which stabilizes the otherwise non-covalent gp120-gp41 interaction.

Abstract: This invention provides methods for eliciting an immune response in a subject comprising administering to the subject as part of a regimen (i) more than one dose of a nucleic acid prime, and (ii) more than one dose of a protein boost composition, wherein each dose of the nucleic acid prime is administered to the subject at a first predefined interval and each dose of the protein boost composition is administered to the subject at a second predefined interval, and wherein the protein boost composition comprises a prophylactically or therapeutically effective dose of (a) a trimeric HIV-1 gp140 protein complex, or (b) a superparamagnetic particle and a trimeric HIV-1 gp140 protein complex so affixed thereto as to permit recognition of the complex by a subject's immune system. The invention also provides methods for prophylactically or therapeutically treating HIV-1 infection in a subject.

Abstract: A method, system, and computer program product that enable integrated scheduling and management of frozen images for backup and recovery purposes. Frozen images are created, cataloged, and managed in accordance with a backup policy including a schedule for generating frozen images. Minimal data are saved to allow fast synchronization of the persistent frozen images with production data, and frozen images are cataloged in a catalog that may include entries for other types of backups to provide a single source of information for all backups of production data.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

Abstract: This invention provides a polypeptide comprising a fragment of a chemokine receptor capable of inhibiting HIV-1 infection. In an embodiment, the chemokine receptor is C—C CKR-5. In another embodiment, the fragment comprises at least one extracellular domain of the chemokine receptor C—C CKR-5. This invention further provides different uses of the chemokine receptor for inhibiting HIV-1 infection.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.